Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 309

The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.

The 2023 nonhormone therapy position statement of The North American Menopause Society

·2023·Menopause

Abstract

Objective: To update the evidence-based Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society. Methods: An advisory panel of clinicians and research experts in women’s health were selected to review and evaluate the literature published since the Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society. Topics were divided into five sections for ease of review: lifestyle; mind-body techniques; prescription therapies; dietary supplements; and acupuncture, other treatments, and technologies. The panel assessed the most current and available literature to determine whether to recommend or not recommend use based on these levels of evidence: Level I, good and consistent scientific evidence; Level II, limited or inconsistent scientific evidence, and Level III, consensus and expert opinion. Results: Evidence-based review of the literature resulted in several nonhormone options for the treatment of vasomotor symptoms. Recommended : Cognitive-behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II-III). Not recommended : Paced respiration (Level I); supplements/herbal remedies (Levels I-II); cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equol, cannabinoids, acupuncture, calibration of neural oscillations (Level II); chiropractic interventions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III). Conclusion: Hormone therapy remains the most effective treatment for vasomotor symptoms and should be considered in menopausal women within 10 years of their final menstrual periods. For women who are not good candidates for hormone therapy because of contraindications (eg, estrogen-dependent cancers or cardiovascular disease) or personal preference, it is important for healthcare professionals to be well informed about nonhormone treatment options for reducing vasomotor symptoms that are supported by the evidence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/gme.0000000000002200

Cites

179 of 179 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 179 references

Research works printed but not linked: 15

  1. 2018, Trends in oral and vaginally administered estrogen use among US women 50 years of age and older with commercial health insurance, Menopause, 25, 611, 10.1097/GME.0000000000001054 · doi:10.1097/gme.0000000000001054
  2. 2019, Dietary patterns and their association with menopausal symptoms: a cross-sectional study, Menopause, 26, 365, 10.1097/GME.0000000000001245 · DOI
  3. 2013, Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials, Gynecol Obstet Invest, 75, 255, 10.1159/000348564 · DOI
  4. 2010, Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients, Acta Derm Venereol, 90, 291, 10.2340/00015555-0828 · doi:10.2340/00015555-0828
  5. The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicentre prospective observational study [published online ahead of print November 26, 2021], Minerva Obstet Gynecol
  6. 2009, Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms, Menopause, 16, 117, 10.1097/gme.0b013e3181806446 · doi:10.1097/gme.0b013e3181806446
  7. 1999, Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid, Planta Med, 65, 763, 10.1055/s-2006-960862 · doi:10.1055/s-2006-960862
  8. 2018, Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women, Climacteric, 21, 69, 10.1080/13697137.2017.1406913 · doi:10.1080/13697137.2017.1406913
  9. 2009, A clinical study on the effect of red ginseng for postmenopausal hot flushes, J Orient Obstet Gynecol, 22, 132
  10. 2007, Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study, Gynecol Endocrinol, 23, 117, 10.1080/09513590701200900 · doi:10.1080/09513590701200900
  11. 2021, The effect of Jazar supplement on quality of life and sexual function in postmenopausal women: a double-blind, randomized, placebo-controlled trial, Evid Based Complement Alternat Med, 8854182
  12. 2020, The maintenance effect of acupuncture on breast cancer-related menopause symptoms: a systematic review, Climacteric, 23, 130, 10.1080/13697137.2019.1664460 · doi:10.1080/13697137.2019.1664460
  13. 2018, Acupuncture for symptoms in menopause transition: a randomized controlled trial, Am J Obstet Gynecol, 219, 373.e1, 10.1016/j.ajog.2018.08.019 · doi:10.1016/j.ajog.2018.08.019
  14. 2022, Electroacupuncture for the treatment of perimenopausal syndrome: a systematic review and meta-analysis of randomized controlled trials, Acupunct Med, 40, 111, 10.1177/09645284211055742 · doi:10.1177/09645284211055742
  15. 2006, Retropharyngeal hematoma after stellate ganglion block: Analysis of 27 patients reported in the literature, Anesthesiology, 105, 1238, 10.1097/00000542-200612000-00024 · doi:10.1097/00000542-200612000-00024

Cited by

See all 309

Metadata

Venue
Menopause
Published
2023-06
Volume
30
Issue
6
Pages
573-590
ISSN
1072-3714 (ISSN-L)
OpenAlex
W4378744965
Cited by
309
References
179
FWCI
51.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 2023 nonhormone therapy position statement of The North American Menopause Society. https://app.cochat.ai/papers/10.1097/gme.0000000000002200
The paper
The 2023 nonhormone therapy position statement of The North American Menopause Society. (2023). Menopause. https://doi.org/10.1097/gme.0000000000002200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.